vs

Side-by-side financial comparison of Blend Labs, Inc. (BLND) and Ginkgo Bioworks Holdings, Inc. (DNA). Click either name above to swap in a different company.

Ginkgo Bioworks Holdings, Inc. is the larger business by last-quarter revenue ($33.4M vs $32.4M, roughly 1.0× Blend Labs, Inc.). On growth, Blend Labs, Inc. posted the faster year-over-year revenue change (7.6% vs -23.8%). Blend Labs, Inc. produced more free cash flow last quarter ($-21.0K vs $-47.7M). Over the past eight quarters, Blend Labs, Inc.'s revenue compounded faster (16.6% CAGR vs -6.2%).

GU Energy Labs is a company based in Berkeley, California, that produces sports nutrition products, most notably energy gels. Often consumed during endurance events, the gels are designed to be quickly and easily digested during any type of activity. Other products include energy chews, drink mixes, hydration tablets, stroopwafels and a Roctane line that includes an energy drink mix, protein recovery drink mix, gel, and capsules. The company was founded in 1994 by Bill Vaughan, who began crea...

Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It...

BLND vs DNA — Head-to-Head

Bigger by revenue
DNA
DNA
1.0× larger
DNA
$33.4M
$32.4M
BLND
Growing faster (revenue YoY)
BLND
BLND
+31.5% gap
BLND
7.6%
-23.8%
DNA
More free cash flow
BLND
BLND
$47.7M more FCF
BLND
$-21.0K
$-47.7M
DNA
Faster 2-yr revenue CAGR
BLND
BLND
Annualised
BLND
16.6%
-6.2%
DNA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BLND
BLND
DNA
DNA
Revenue
$32.4M
$33.4M
Net Profit
$-2.5M
Gross Margin
75.7%
Operating Margin
-11.1%
-211.9%
Net Margin
-7.8%
Revenue YoY
7.6%
-23.8%
Net Profit YoY
-207.0%
EPS (diluted)
$-1.41

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BLND
BLND
DNA
DNA
Q4 25
$32.4M
$33.4M
Q3 25
$32.7M
$38.8M
Q2 25
$31.6M
$49.6M
Q1 25
$26.8M
$48.3M
Q4 24
$30.1M
$43.8M
Q3 24
$33.1M
$89.0M
Q2 24
$28.7M
$56.2M
Q1 24
$23.8M
$37.9M
Net Profit
BLND
BLND
DNA
DNA
Q4 25
$-2.5M
Q3 25
$12.1M
$-80.8M
Q2 25
$-6.8M
$-60.3M
Q1 25
$-9.5M
$-91.0M
Q4 24
$-825.0K
Q3 24
$-2.4M
$-56.4M
Q2 24
$-19.4M
$-217.2M
Q1 24
$-20.7M
$-165.9M
Gross Margin
BLND
BLND
DNA
DNA
Q4 25
75.7%
Q3 25
74.3%
Q2 25
73.8%
Q1 25
70.8%
Q4 24
74.2%
Q3 24
74.0%
Q2 24
70.9%
Q1 24
67.3%
Operating Margin
BLND
BLND
DNA
DNA
Q4 25
-11.1%
-211.9%
Q3 25
-16.4%
-231.8%
Q2 25
-15.3%
-132.1%
Q1 25
-29.7%
-184.1%
Q4 24
-10.9%
-236.3%
Q3 24
-34.1%
-62.0%
Q2 24
-45.5%
-396.7%
Q1 24
-89.0%
-469.1%
Net Margin
BLND
BLND
DNA
DNA
Q4 25
-7.8%
Q3 25
37.0%
-207.9%
Q2 25
-21.6%
-121.6%
Q1 25
-35.5%
-188.2%
Q4 24
-2.7%
Q3 24
-7.4%
-63.3%
Q2 24
-67.6%
-386.4%
Q1 24
-86.7%
-437.3%
EPS (diluted)
BLND
BLND
DNA
DNA
Q4 25
$-1.41
Q3 25
$0.02
$-1.45
Q2 25
$-1.10
Q1 25
$-1.68
Q4 24
$-0.03
$-1.91
Q3 24
$-0.03
$-1.08
Q2 24
$-0.09
$-4.23
Q1 24
$-0.09
$-3.32

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BLND
BLND
DNA
DNA
Cash + ST InvestmentsLiquidity on hand
$68.3M
$422.6M
Total DebtLower is stronger
$0
Stockholders' EquityBook value
$-30.5M
$508.6M
Total Assets
$170.0M
$1.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BLND
BLND
DNA
DNA
Q4 25
$68.3M
$422.6M
Q3 25
$77.3M
$495.5M
Q2 25
$88.3M
$559.4M
Q1 25
$104.8M
$325.3M
Q4 24
$94.2M
$561.6M
Q3 24
$112.3M
$616.2M
Q2 24
$108.9M
$730.4M
Q1 24
$121.1M
$840.4M
Total Debt
BLND
BLND
DNA
DNA
Q4 25
$0
Q3 25
$0
Q2 25
$0
Q1 25
$0
Q4 24
$0
Q3 24
$0
Q2 24
$0
Q1 24
$138.9M
Stockholders' Equity
BLND
BLND
DNA
DNA
Q4 25
$-30.5M
$508.6M
Q3 25
$-13.4M
$559.8M
Q2 25
$-23.1M
$613.0M
Q1 25
$-17.2M
$647.4M
Q4 24
$-56.4M
$716.1M
Q3 24
$-49.6M
$797.9M
Q2 24
$-45.5M
$833.1M
Q1 24
$-35.8M
$987.3M
Total Assets
BLND
BLND
DNA
DNA
Q4 25
$170.0M
$1.1B
Q3 25
$188.6M
$1.2B
Q2 25
$182.2M
$1.2B
Q1 25
$187.5M
$1.3B
Q4 24
$178.1M
$1.4B
Q3 24
$186.1M
$1.5B
Q2 24
$185.4M
$1.6B
Q1 24
$201.8M
$1.6B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BLND
BLND
DNA
DNA
Operating Cash FlowLast quarter
$1.5M
$-47.7M
Free Cash FlowOCF − Capex
$-21.0K
$-47.7M
FCF MarginFCF / Revenue
-0.1%
-142.8%
Capex IntensityCapex / Revenue
4.8%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-81.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BLND
BLND
DNA
DNA
Q4 25
$1.5M
$-47.7M
Q3 25
$-3.6M
$-31.6M
Q2 25
$-6.5M
$-40.3M
Q1 25
$20.1M
$-51.5M
Q4 24
$-4.6M
$-42.4M
Q3 24
$2.1M
$-103.5M
Q2 24
$-6.7M
$-84.4M
Q1 24
$-3.9M
$-89.3M
Free Cash Flow
BLND
BLND
DNA
DNA
Q4 25
$-21.0K
$-47.7M
Q3 25
$-5.8M
Q2 25
$-10.1M
$-40.3M
Q1 25
$15.8M
$-59.1M
Q4 24
$-7.1M
$-56.1M
Q3 24
$-1.4M
$-118.6M
Q2 24
$-8.5M
$-111.4M
Q1 24
$-5.8M
$-96.0M
FCF Margin
BLND
BLND
DNA
DNA
Q4 25
-0.1%
-142.8%
Q3 25
-17.6%
Q2 25
-31.9%
-81.2%
Q1 25
58.9%
-122.4%
Q4 24
-23.5%
-128.0%
Q3 24
-4.1%
-133.2%
Q2 24
-29.7%
-198.2%
Q1 24
-24.5%
-252.9%
Capex Intensity
BLND
BLND
DNA
DNA
Q4 25
4.8%
0.0%
Q3 25
6.5%
0.0%
Q2 25
11.4%
0.1%
Q1 25
16.1%
15.8%
Q4 24
8.3%
31.3%
Q3 24
10.4%
16.9%
Q2 24
6.5%
48.1%
Q1 24
8.2%
17.7%
Cash Conversion
BLND
BLND
DNA
DNA
Q4 25
Q3 25
-0.30×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BLND
BLND

Mortgage Suite$18.9M58%
Consumer Banking Suite$11.4M35%
Professional Services$2.1M6%

DNA
DNA

Cell Engineering Segment$26.0M78%
Other$7.4M22%

Related Comparisons